Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
F, female; M, male; EG, experimental group; CG, control group; TPTD, Teriparatide; ALN, alendronate; RID, risedronate; ZOL, zoledronate; Vit D, vitamin D; Outcomes (the outcomes recorded in the study) ①: Incidence of Vertebral Fractures;②: Incidence of Non-Vertebral Fractures; ③: 12-Month Increase Rate of Lumbar Spine BMD; ④: 12-Month Increase Rate of Femoral Neck BMD; ⑤: 18-Month or Longer Increase Rate of Lumbar Spine BMD; ⑥: 18-Month or Longer Increase Rate of Femoral Neck BMD.
Source: Basic characteristics of included studies. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Comparative efficacy and safety of teriparatide versus bisphosphonates in osteoporosis: a meta-analysis
Source: Article title.
Publisher article type: review-article
Source: Publisher publication metadata.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Comparative efficacy and safety of teriparatide versus bisphosphonates in osteoporosis: a meta-analysis
Review / evidence synthesis · Frontiers in Surgery · 2025
Original publication title
Comparative efficacy and safety of teriparatide versus bisphosphonates in osteoporosis: a meta-analysis
© 2025 Jin, Dong, Huang, Wang, He, Shen, Ma, Wang, Shi and Shuai.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This meta-analysis systematically compared the efficacy and safety of teriparatide and bisphosphonates in treating osteoporosis (OP) to inform optimal treatment strategies.
Source: ObjectivesAbstract: What methods does the paper describe?
A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, Web of Science, and Google Scholar from inception through October 2024. Randomized controlled trials comparing teriparatide and bisphosphonates for OP were included. Primary outcomes included vertebral/non-vertebral fracture risk reduction and lumbar spine/femoral neck bone mineral density (BMD) improvements. Data were analyzed using RevMan 5.3, with dichotomous data assessed via odds ratios (OR) and continuous data via mean differences (MD), both reported with 95% confidence intervals (CI).
Source: MethodsAbstract: Results
Thirteen studies involving 4,420 patients were analyzed (six Grade A, four Grade B, three Grade C). Teriparatide significantly reduced vertebral [OR = 0.40, 95% CI = (0.33, 0.49), p < 0.00001] and non-vertebral fracture risks [OR = 0.58, 95% CI = (0.54, 0.70), p < 0.00001] compared to bisphosphonates. At 12 months, teriparatide showed greater improvements in lumbar spine BMD [MD = 2.72, 95% CI = (2.44, 3.00), p < 0.00001] and femoral neck BMD [MD = 1.66, 95% CI = (0.42, 2.90), p = 0.0090].
In studies with >18-month follow-ups, teriparatide maintained superior lumbar spine BMD [MD = 4.65, 95% CI = (4.28, 5.03), p < 0.00001] and femoral neck BMD [MD = 1.42, 95% CI = (0.57, 2.26), p = 0.0010] improvements. Adverse event rates were comparable between teriparatide and bisphosphonates [MD = 1.03, 95% CI = (0.88, 1.20), p = 0.73].
Source: ResultsAbstract: Conclusion
Teriparatide demonstrated superior efficacy in reducing vertebral/non-vertebral fracture risks and improving BMD in both short: and long-term treatments, with a safety profile comparable to bisphosphonates.
Source: ConclusionAuthors’ abstract
Objectives
This meta-analysis systematically compared the efficacy and safety of teriparatide and bisphosphonates in treating osteoporosis (OP) to inform optimal treatment strategies.
Methods
A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, Web of Science, and Google Scholar from inception through October 2024. Randomized controlled trials comparing teriparatide and bisphosphonates for OP were included. Primary outcomes included vertebral/non-vertebral fracture risk reduction and lumbar spine/femoral neck bone mineral density (BMD) improvements. Data were analyzed using RevMan 5.3, with dichotomous data assessed via odds ratios (OR) and continuous data via mean differences (MD), both reported with 95% confidence intervals (CI).
Results
Thirteen studies involving 4,420 patients were analyzed (six Grade A, four Grade B, three Grade C). Teriparatide significantly reduced vertebral [OR = 0.40, 95% CI = (0.33, 0.49), p < 0.00001] and non-vertebral fracture risks [OR = 0.58, 95% CI = (0.54, 0.70), p < 0.00001] compared to bisphosphonates. At 12 months, teriparatide showed greater improvements in lumbar spine BMD [MD = 2.72, 95% CI = (2.44, 3.00), p < 0.00001] and femoral neck BMD [MD = 1.66, 95% CI = (0.42, 2.90), p = 0.0090].
In studies with >18-month follow-ups, teriparatide maintained superior lumbar spine BMD [MD = 4.65, 95% CI = (4.28, 5.03), p < 0.00001] and femoral neck BMD [MD = 1.42, 95% CI = (0.57, 2.26), p = 0.0010] improvements. Adverse event rates were comparable between teriparatide and bisphosphonates [MD = 1.03, 95% CI = (0.88, 1.20), p = 0.73].
Conclusion
Teriparatide demonstrated superior efficacy in reducing vertebral/non-vertebral fracture risks and improving BMD in both short: and long-term treatments, with a safety profile comparable to bisphosphonates.
Publication and source details
Original title: Comparative efficacy and safety of teriparatide versus bisphosphonates in osteoporosis: a meta-analysis
Huan Jin; Ying Dong; Cai Huang; Di Wang; Ziyi He; Lin Shen; Chen Ma; Zixian Wang; Siwei Shi; Bo Shuai
Frontiers in Surgery · 2025
* Correspondence: Bo Shuai bo_shuai@hust.edu.cn© 2025 Jin, Dong, Huang, Wang, He, Shen, Ma, Wang, Shi and Shuai.2025Jin, Dong, Huang, Wang, He, Shen, Ma, Wang, Shi and Shuaihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. National Natural Science Foundation of China10.13039/501100001809 The author(s) declared financial support was received for the research and/or publication of this article. This study was partially funded by the National Natural Science Foundation of China (Project Numbers: 82174182, 81974546), the Scientific Research Project of Hubei Provincial Administration of Traditional Chinese Medicine (Project Number: ZY2025Q031), the Shizhen Talent Program of Hubei Province for Scientific Research [Project Number: Hubei Health Document (2024) No. 256].Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:15:19.965616+00:00
DOI: 10.3389/fsurg.2025.1582180 · PMC12719462